Shares of Cel-Sci Corp (CVM) are trading 10% higher at a price of $4.66 at the time of this writing. The Health Care sector is having a generally mildly positive day, this hasn't really affected the stock's share price, as it outperforming other names in the space.

Cel-Sci Corp has been trading between a 52-week high of $12.9 and a 52-week low of $2.49. The stock has a market cap of $202 Million.

CEL-SCI believes that boosting a patient’s immune system while it is still intact should provide the greatest possible impact on survival. Therefore, in the Phase 3 study CEL-SCI treated patients who are newly diagnosed with advanced primary squamous cell carcinoma of the head and neck, are treated with the investigational product Multikine first, BEFORE they received surgery, radiation and/or chemotherapy (the current standard of care for these patients). This approach is unique.

CEL-SCI Corporation Announces Phase 3 Multikine Head and Neck Cancer Results Posted on Clinicaltrials.gov
Wallstreet:Online 08-19-22

This Financial Services Stock Surged Around 116%; Here Are 86 Biggest Movers From Yesterday
Benzinga 08-16-22

Cel-Sci GAAP EPS of -$0.66 (NYSE:CVM)
Seeking Alpha 08-15-22

CEL-SCI Corporation Reports Third Quarter Fiscal 2022 Financial Results
Business Wire 08-15-22

CEL-SCI Corporation Announces Reddit AMA with Geert Kersten
Wallstreet:Online 07-14-22